Left ventricular hypertrophy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:16:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Left ventricular hypertrophy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of CDR132L on Heart Structure and Function in Patients with Heart Failure and Left Ventricular Hypertrophy https://clinicaltrials.eu/trial/study-on-the-effects-of-cdr132l-on-heart-structure-and-function-in-patients-with-heart-failure-and-left-ventricular-hypertrophy/ Wed, 29 Apr 2026 15:05:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-cdr132l-on-heart-structure-and-function-in-patients-with-heart-failure-and-left-ventricular-hypertrophy/ This clinical trial is focused on studying a condition known as Heart Failure with Preserved Ejection Fraction (HFpEF) and Left Ventricular Hypertrophy (LVH). These are heart conditions where the heart muscle is thickened and the heart’s ability to pump blood is affected, but the heart’s pumping capacity remains normal. The study will test a treatment called CDR132L, which is a type of medication made from nucleic acids, a basic building block of life. The trial will compare different doses of CDR132L with a placebo to see how they affect the heart’s structure and function in people with these conditions.

The purpose of the study is to see if CDR132L can improve heart health by changing certain markers in the blood, specifically something called miR-132, over a period of 24 weeks. Participants will receive either CDR132L or a placebo, in addition to their usual heart failure treatments. The study will monitor changes in the heart’s structure and function, as well as any side effects, over the course of the trial.

Participants will be involved in the study for up to 60 weeks, during which they will have regular check-ups to assess their heart health and overall well-being. The study aims to provide valuable information on whether CDR132L can be a beneficial treatment for people with HFpEF and LVH, potentially leading to better management of these heart conditions in the future.

]]> Study on CDR132L for Heart Failure with Reduced Ejection Fraction and Left Ventricular Hypertrophy in Adults https://clinicaltrials.eu/trial/study-on-cdr132l-for-heart-failure-with-reduced-ejection-fraction-and-left-ventricular-hypertrophy-in-adults/ Wed, 29 Apr 2026 15:05:01 +0000 https://clinicaltrials.eu/trial/study-on-cdr132l-for-heart-failure-with-reduced-ejection-fraction-and-left-ventricular-hypertrophy-in-adults/ This clinical trial is focused on studying heart failure in individuals who have a reduced or mildly reduced ability of the heart to pump blood, known as ejection fraction, along with a condition called left ventricular hypertrophy, which is a thickening of the heart’s main pumping chamber. The study will test a treatment called CDR132L, which is a type of nucleic acid therapy. This treatment will be compared to a placebo to see how it affects the heart’s structure and function.

The purpose of the study is to determine if CDR132L is more effective than a placebo in improving heart health in participants. The study will last for several months, during which participants will receive either the CDR132L treatment or a placebo, in addition to their usual heart failure care. The main focus will be on changes in a specific molecule called miR-132 over a 24-week period. Participants will be monitored for any changes in their heart condition and any side effects they may experience.

Throughout the study, participants will undergo regular check-ups to assess their heart’s function and overall health. The study aims to provide valuable information on the potential benefits of CDR132L for people with heart failure and left ventricular hypertrophy, contributing to better treatment options in the future.

]]> Study on Dapagliflozin for Patients with Chronic Kidney Disease or Kidney Failure Undergoing Hemodialysis https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-chronic-kidney-disease-or-kidney-failure-undergoing-hemodialysis/ Wed, 29 Apr 2026 15:02:29 +0000 https://clinicaltrials.eu/trial/study-on-dapagliflozin-for-patients-with-chronic-kidney-disease-or-kidney-failure-undergoing-hemodialysis/ This clinical trial is focused on studying the effects of a medication called dapagliflozin, which is marketed under the name Forxiga, in patients undergoing hemodialysis. Hemodialysis is a treatment for people with severe kidney problems, such as Chronic Kidney Disease and Kidney Failure. The study also looks at patients with a heart condition known as Left Ventricular Hypertrophy, which is a thickening of the heart’s left pumping chamber. The purpose of the study is to compare the effects of dapagliflozin with a placebo on heart health in these patients.

Participants in the study will be randomly assigned to receive either dapagliflozin or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for about six months, during which time the participants will continue their regular hemodialysis treatments while taking the study medication or placebo. The main focus will be on changes in the heart’s structure and function, particularly the Left Ventricular Mass, which is a measure of the heart’s size and health.

Throughout the study, various health markers will be monitored, including blood sugar levels, hormones, and heart function indicators. The goal is to see if dapagliflozin can improve heart health and overall quality of life for patients on hemodialysis. The study will provide valuable information on whether this medication can be beneficial for people with kidney and heart conditions who are undergoing hemodialysis.

]]>